The addition of daratumumab (Darzalex) to up-front triplet and quadruplet regimens in multiple myeloma has contributed to increased depth and durability of response, and although minimal residual disease (MRD) assessment has proven to be a sensitive and specific means of assessing the likelihood and length of remission in a research setting, it should not yet be used to direct treatment decisions, said Marc J. Braunstein, MD, PhD, who instead highlighted patient fitness as one of the primary measures upon which to base initial interventions.
What we aim to do in the field is figure out how to best tailor combinations of these therapies in order to produce the longest duration of remission and the longest overall survival. Many trials are using MRD as an end point in order to look at the deepest possible remissions that we can achieve using various combinations of these novel agents, said Braunstein.
In an interview with OncLiveduring a 2020 Institutional Perspectives in Cancer webinar on multiple myeloma, Braunstein, assistant professor in the Department of Medicine at NYU Long Island School of Medicine; course co-director of the Hematology-Oncology System and co-director of the Autologous Stem Cell Transplant Program, NYU Winthrop Hospital of NYU Langone Healths Perlmutter Cancer Center,discussed the current landscape of newly diagnosed multiple myeloma and the utility of MRD in the research sphere.
Braunstein: Were seeing a tremendous expansion of the armamentarium of agents we have to treat newly diagnosed and relapsed/refractory multiple myeloma. In the past 4 or 5 years, weve seen an increase in the use of monoclonal antibodies targeting various antigens on the surface of malignant plasma cells in newly diagnosed and relapsed/refractory myeloma. Were also seeing an increase in the use of additional agents targeting various mechanisms of neoplastic myeloma cells, including inhibitors of nuclear export, as well as inhibitors of BCMA.
What we aim to do in the field is figure out how to best tailor combinations of these therapies in order to produce the longest duration of remission and the longest overall survival. Many trials are using MRD as an end point in order to look at the deepest possible remissions that we can achieve using various combinations of these novel agents.
MRD is used in many other hematologic malignancies but is now becoming more standard in terms of regulatory approval for novel agents, and in clinical trials as a primary end point. MRD is a measure of how deep a remission you can achieve in a patient with multiple myeloma. There are 2 primary assays that are used to assess this: one is flow cytometry, where youre looking with various markers on plasma cells to see how many residual cells there are at the end of treatment, and the other assay is an FDA-approved assay that uses next-generation sequencing to compare the initial clone when the patient was first diagnosed to see if there are any residual clones compared with their diagnosis at the end of treatment. Therefore, you need a comparator sample for that assay. They each have pros and cons. Both are able to look at the depth of MRD at a level between 10-5 and 10-6 remaining cells. They definitely are useful in terms of being very sensitive, and even specific.
The question we have yet to answer is how to make certain treatment decisions depending on whether a patient has MRD, despite having a deep remission by standard assessment criteria. [For example], if the patient has a complete or stringent complete remission [CR] but is still MRD positive, we still have unanswered questions about what to do with those patients after induction. Nevertheless, its clear that patients who do achieve MRD negativity have much better overall outcomes, including better survival than those who remain MRD positive. This can be a very valuable end point for clinical trials, because it can be assessed relatively easy without waiting for the duration of PFS that is historically used as the primary end point.
In terms of community uptake of MRD assays, it still varies. Theres no one standard assay thats used from office to office. Were going to be seeing more use of MRD, both in clinical trials and in practice. As time goes on, well have answers to more important questions, such as what to do when you have a patient who is persistently MRD positive or goes from being MRD negative to MRD positive, despite absence of other indices of progressive or relapsed disease.
There is an art to managing patients with multiple myeloma. Patients are best served by seeing clinicians who manage a larger cohort of myeloma patients in order to help them navigate through all the different options as well as assess the patients fitness. In oncology, were accustomed to assessing how fit a patient is in terms of their performance status. But even more so in multiple myeloma, we now have data supporting the use of frailty scores that take into account a more comprehensive assessment of the patients fitness for more or less intensive therapies.
Determining how fit a patient is has to be the first assessment that is made [to understand their eligibility for] the various lines of therapies as well as the trajectory for consolidation with autologous stem cell transplant [ASCT]. A lot of new data and updates of studies have compared the role of up-front ASCT versus standard of care agents, and weve seen better outcomes when we consolidate the disease with ASCT in those who are eligible.
When it comes to assessing and treating newly diagnosed patients with multiple myeloma, we have several combination regimens, including 2-, 3-, and 4-drug combinations. Thats why we really have to tailor and individualize our treatment decisions for these patients. Weve seen a lot of new data in the past few years as well as updates at the recent 2020 ASH Annual Meeting and Exposition for the inclusion of daratumumab, which targets CD38 on myeloma plasma cells, as part of triplet and quadruplet regimens. The combination of daratumumab, lenalidomide [Revlimid] and dexamethasone was studied in the phase 3 MAIA study, and showed impressive outcomes at a 48-month median follow-up. The [48-month] progression-free survival [PFS] rate was 60%, and the median PFS hadnt been reached in the triplet arm.
In transplant-eligible patients, we saw impressive data from the phase 2 GRIFFIN study, which was presented by Jonathan Kaufman, MD, of Winship Cancer Institute, and colleagues as an update at the 2020 ASH Annual Meeting and Exposition, showing that at 12 months of follow-up, at every step from induction through transplant, consolidation, and maintenance, patients who got the quadruplet regimen of daratumumab, lenalidomide, bortezomib [Velcade], and dexamethasone [D-RVd] had better overall outcomes compared with patients who received lenalidomide, bortezomib, and dexamethasone alone; this included depth of response and MRD negativity. At our institution, we have adopted this regimen of D-RVd for fit patients who are transplant eligible.
The initial randomized data we saw for the use of monoclonal antibodies in multiple myeloma was demonstrated in the relapsed/refractory setting after at least one line of therapy. In those studies, we saw impressive results in terms of the PFS when daratumumab was combined with 2 other agents, either bortezomib and dexamethasone, or lenalidomide and dexamethasone in the POLLUX and CASTOR studies, respectively. Those pivotal phase 3 studies showed a PFS [benefit] in the triplet arm versus the control arm, even in high-risk patients.
Now, when we when we look at the data for the up-front use of daratumumab for patients [with newly] diagnosed multiple myeloma, we do see impressive results in quadruplet or triplet regimens compared with controls that do not contain a monoclonal antibody when it comes to PFS and MRD negativity. However, we have not yet seen a benefit for high-risk patients. A meta-analysis showed a possible signal of benefit in those patients, but in the individual studies, either MAIA, ALCYONE, CASSIOPEIA, or GRIFFIN, we didnt exactly see a benefit in the subgroup analysis for high-risk patients, although the numbers of those patients were relatively small. Were going to be seeing increasing use of monoclonal antibodies up front for multiple myeloma.
In the relapsed/refractory setting, were not only going to be seeing an increased use of these immunotherapies, but also an increased array of options that target different antigens on myeloma cells. The most recently approved antibody we have for relapsed/refractory disease is belantamab mafodotin [Blenrep], which is the first-in-class antibody that targets BCMA. Its also an antibody-drug conjugate that delivers cytotoxin directly to the plasma cells. This was studied in the relapsed/refractory setting and updated data were presented at the 2020 ASH Annual Meeting and Exposition. In combination with other conventional agents, we see between a 60% to 70% overall response rate in very refractory patients. Were going to have a lot more options in terms of monoclonal antibodies, including ones that target novel agents that are in preclinical or early phase studies, such as BAFF, RASi, and other surface antigens that are in the pipeline that are being targeted.
One of the one of the advantages of treating multiple myeloma is theres so much progress being made. One of the detriments is that it can be challenging to determine how were going to sequence these agents. However, thats a good problem to have, and were going to have many more options for patients who progress.
More here:
MRD Could Prove to Be a Valuable Tool in Multiple Myeloma - OncLive
- Using stem cell-derived heart muscle cells to advance heart regenerative therapy - Medical Xpress - April 28th, 2024
- John Cleese is spending thousands on stem cell therapy is it really the secret to anti-ageing? - Yahoo Lifestyle Australia - April 28th, 2024
- SUM Hospital conducts Odishas first stem cell transplantation - The Times of India - April 24th, 2024
- Cancer treatment: What is stem cell therapy, and how does it work? - Moneycontrol - April 24th, 2024
- The murky, unregulated world of anti-ageing stem cell therapy - The Telegraph - April 24th, 2024
- Drug Prototype Promising in Treatment of Pulmonary Disease - Medscape - April 20th, 2024
- Man Paralyzed In Surfing Accident Regains Ability to Walk After Stem Cell Treatment - The Inertia - April 20th, 2024
- Medical breakthrough: 8-year-old boy first in New York to receive FDA-approved gene therapy for rare inherited blood disorder - WABC-TV - April 20th, 2024
- Stem Cell Treatment Helped A Man Who Was Paralyzed From The Neck Down To Stand On His Own - Bored Panda - April 20th, 2024
- UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo - April 20th, 2024
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
Recent Comments